Evidence map›Paper›PMID 25590131›Full record

ArticlePLoS pathogens2015

Promiscuous RNA binding ensures effective encapsidation of APOBEC3 proteins by HIV-1.

Luis Apolonia, Reiner Schulz, Tomaž Curk, Paula Rocha, Chad M Swanson, Torsten Schaller, Jernej Ule, Michael H Malim

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
7.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 92 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Luis ApoloniaDepartment of Infectious Diseases, King's College London, London, United Kingdom.
Reiner SchulzDepartment of Medical and Molecular Genetics, King's College London, London, United Kingdom.
Tomaž CurkFaculty of Computer and Information Science, University of Ljubljana, Ljubljana, Slovenia.
Paula RochaDepartment of Statistical Science, University College London, London, United Kingdom.
Chad M SwansonDepartment of Infectious Diseases, King's College London, London, United Kingdom.
Torsten SchallerDepartment of Infectious Diseases, King's College London, London, United Kingdom.
Jernej UleMedical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom; Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, United Kingdom.
Michael H MalimMedical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom.
King's College London · GBMRC Laboratory of Molecular Biology · GBNational Hospital for Neurology and Neurosurgery · GBUniversity College London · GBUniversity of Ljubljana · SI

Funding

Department of HealthMedical Research Council G1000196Medical Research Council G1001081Medical Research Council MC_U105185858Medical Research Council MR/K000381/1Medical Research Council MR/M001199/1
6 · The paper itself

Abstract

The apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 (APOBEC3) proteins are cell-encoded cytidine deaminases, some of which, such as APOBEC3G (A3G) and APOBEC3F (A3F), act as potent human immunodeficiency virus type-1 (HIV-1) restriction factors. These proteins require packaging into HIV-1 particles to exert their antiviral activities, but the molecular mechanism by which this occurs is incompletely understood. The nucleocapsid (NC) region of HIV-1 Gag is required for efficient incorporation of A3G and A3F, and the interaction between A3G and NC has previously been shown to be RNA-dependent. Here, we address this issue in detail by first determining which RNAs are able to bind to A3G and A3F in HV-1 infected cells, as well as in cell-free virions, using the unbiased individual-nucleotide resolution UV cross-linking and immunoprecipitation (iCLIP) method. We show that A3G and A3F bind many different types of RNA, including HIV-1 RNA, cellular mRNAs and small non-coding RNAs such as the Y or 7SL RNAs. Interestingly, A3G/F incorporation is unaffected when the levels of packaged HIV-1 genomic RNA (gRNA) and 7SL RNA are reduced, implying that these RNAs are not essential for efficient A3G/F packaging. Confirming earlier work, HIV-1 particles formed with Gag lacking the NC domain (Gag ΔNC) fail to encapsidate A3G/F. Here, we exploit this system by demonstrating that the addition of an assortment of heterologous RNA-binding proteins and domains to Gag ΔNC efficiently restored A3G/F packaging, indicating that A3G and A3F have the ability to engage multiple RNAs to ensure viral encapsidation. We propose that the rather indiscriminate RNA binding characteristics of A3G and A3F promote functionality by enabling recruitment into a wide range of retroviral particles whose packaged RNA genomes comprise divergent sequences.

Indexed as

APOBEC-3G DeaminaseAPOBEC DeaminasesAutoantigensCells, CulturedCytidine DeaminaseCytosine DeaminaseHEK293 CellsHeLa CellsHIV-1HumansProtein BindingRibonucleoproteinsRNA, Small CytoplasmicRNA, Small UntranslatedSignal Recognition ParticleSS-A Antigen7SL RNAAPOBEC3F protein, humanAPOBEC-3G DeaminaseAPOBEC3G protein, humanAPOBEC3 proteins, humanAPOBEC DeaminasesAutoantigensCytidine DeaminaseCytosine DeaminaseRibonucleoproteinsRNA, Small CytoplasmicRNA, Small UntranslatedRO60 protein, humanSignal Recognition ParticleSS-A Antigen

Identifiers

PMID25590131
PMCPMC4295846
OpenAlexW1969475895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.